NASDAQ:MYOS - MYOS Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.29 +0.04 (+3.20 %) (As of 09/20/2018 04:00 PM ET)Previous Close$1.25Today's Range$1.25 - $1.2952-Week Range$1.03 - $2.50Volume17,617 shsAverage Volume14,835 shsMarket Capitalization$8.86 millionP/E Ratio-1.87Dividend YieldN/ABeta1.41 Company ProfileDiscussionChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of FortetropinÂ on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey. Receive MYOS News and Ratings via Email Sign-up to receive the latest news and ratings for MYOS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:MYOS CUSIPN/A Webwww.myoscorp.com Phone973-509-0444 Debt Debt-to-Equity RatioN/A Current Ratio5.80 Quick Ratio1.51 Price-To-Earnings Trailing P/E Ratio-1.87 Forward P/E Ratio-2.15 P/E GrowthN/A Sales & Book Value Annual Sales$530,000.00 Price / Sales16.21 Cash FlowN/A Price / CashN/A Book Value$0.69 per share Price / Book1.87 Profitability EPS (Most Recent Fiscal Year)($0.69) Net Income$-4,050,000.00 Net Margins-883.55% Return on Equity-101.86% Return on Assets-91.68% Miscellaneous Employees10 Outstanding Shares6,660,000Market Cap$8.86 million MYOS (NASDAQ:MYOS) Frequently Asked Questions What is MYOS's stock symbol? MYOS trades on the NASDAQ under the ticker symbol "MYOS." How were MYOS's earnings last quarter? MYOS Co. (NASDAQ:MYOS) released its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.06. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.20 million. MYOS had a negative net margin of 883.55% and a negative return on equity of 101.86%. View MYOS's Earnings History. When is MYOS's next earnings date? MYOS is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for MYOS. Who are some of MYOS's key competitors? Some companies that are related to MYOS include Capricor Therapeutics (CAPR), ProPhase Labs (PRPH), Vistagen Therapeutics (VTGN), Lipocine (LPCN), SUMMIT THERAPEU/S (SMMT), Gemphire Therapeutics (GEMP), vTv Therapeutics (VTVT), Jaguar Health (JAGX), AEterna Zentaris (AEZS), Provectus Biopharmaceuticals (PVCT), BENITEC BIOPHAR/S (BNTC), KITOV PHARMA LT/S (KTOV), Soligenix (SNGX), OvaScience (OVAS) and X T L Biopharmaceuticals (XTLB). Who are MYOS's key executives? MYOS's management team includes the folowing people: Mr. Joseph Mannello, CEO & Director (Age 60)Mr. Ren Ren, Global Chairman (Age 56)Mr. Joseph DiPietro, ControllerMr. Magshoud Dariani, Chief Technology OfficerMr. Dominick Commesso, Exec. VP of Sales and Marketing Has MYOS been receiving favorable news coverage? Media coverage about MYOS stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MYOS earned a news impact score of 0.18 on Accern's scale. They also gave headlines about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for MYOS. How do I buy shares of MYOS? Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is MYOS's stock price today? One share of MYOS stock can currently be purchased for approximately $1.29. How big of a company is MYOS? MYOS has a market capitalization of $8.86 million and generates $530,000.00 in revenue each year. The company earns $-4,050,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. MYOS employs 10 workers across the globe. How can I contact MYOS? MYOS's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected] MarketBeat Community Rating for MYOS (NASDAQ MYOS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 60 (Vote Outperform)Underperform Votes: 60 (Vote Underperform)Total Votes: 120MarketBeat's community ratings are surveys of what our community members think about MYOS and other stocks. Vote "Outperform" if you believe MYOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: What is a Stop Order?